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ABSTRACT
Quality of product and safety of product usage is of key importance in different 
industries specifi cally in health and pharmaceutical industry. Internet becomes a 
framework for new e-economy development bringing new and inventive opportuni-
ties for business development. But in the same time Internet becomes largest channel 
for selling fake, counterfeit and misbranded products and pharmaceutical products 
specially, threating people’s life and public health. To solve this problem number of 
countries in the world started implementation of track and trace systems that will 
enable customer and authorities to track production and logistic chain for specifi c 
product from the trader, to the producer and even to the row material producer of 
product. This is not a simple task, since it requires adequate legal framework and 
information technology system development. The purpose of this paper is to explain 
legal framework and information technology terms and procedures related with seri-
alization. A brief overview of serialization implementation in different countries and 
EU is given. Legal and IT framework is presented for EU. Product counterfeiting is 
a general problem which importance grows in e-commerce environment. Thus se-
rialization in pharmaceutical industries is just beginning; it will be base for future 
development and spreading this solution in other industries as well. 
1. INTRODUCTION
The application of different information technologies (IT) makes our world 
functioning.  IT technologies applications optimize business processes within 
or between different organizations, and today there is not even single aspect 
of business process in which IT does not take important role. The product 
which we are purchasing and using has to fulfi ll our needs and wishes. Product 
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characteristics must be declared, since it is base for searching and selecting 
them on Internet. In Internet and e-commerce environment customer has no 
physical contact with product. Thus description, photo, video or virtual reality 
presentation and of course, the brand are source of information and selection 
for customer. Product information is mainly generated by the trader or produc-
er, but some of the additional information can be generated by product user, 
their product ratings, experiences and opinions are published on the product 
web page, distributed thru different social services and social networks. 
Nevertheless in product selection process one of the strongest infl uences be-
side the price, has the product brand as well. We are usually more attracted 
by the product with better brand image. It is no wonder since the brand is 
tightly connected with company reputation and quality of the product. But 
large proportion of products on the market, in the stores, on Internet is fake 
products. Fake medicine or food can be dangerous or even lethal. Product se-
rialization shall ensure customer that the product which he or she are paying 
is original, not fake, and not counterfeit and that this product has required 
and declared characteristics. Serialization is base for any track and trace sys-
tem, “it is assignment a unique traceable number to each saleable package unit 
of product”1. A serial number must be assigned to each container as product 
moves thru different package phases. Every blister, bottle, box or pallet must 
be uniquely identifi ed with serial number. 
2. SERIALIZATION IMPLEMENTATION BRIEF OVERVIEW
One of the key events in serialization introduction into practice was Prescrip-
tion Drug Marketing Act (PDMA) in USA from 1987. “The PDMA was en-
acted (1) to ensure that drug products purchased by consumers are safe and 
effective, and (2) to avoid the unacceptable risk to American consumers from 
counterfeit, adulterated, misbranded, sub potent, or expired drugs. The legis-
lation was necessary to increase safeguards in the drug distribution system to 
prevent the introduction and retail sale of substandard, ineffective, or coun-
terfeit drugs”2. Soon special Counterfeit Drug Task Force was established in 
2003 by FDA to enhance the existing safeguards that are in place to protect the 
nation’s drug supply from counterfeit drugs.3.
1 Buker Dana, Loy David: Serialization – A Worldwide Challenge, Pharmaceutical Engi-
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In 2003 Belgium published a Royal Decree4 introducing obligation of sequen-
tial codes application on all medicine products to identify uniquely every 
product pack. All packages from 2004 must have 16-digit bar code product 
identifi cation number. In USA 2004 California Ridley-Thomas Pharmacy Ped-
igree SB 1307 establish base to provide “means an electronic record contain-
ing information regarding each transaction resulting in a change of ownership 
of a given dangerous drug, from sale by a manufacturer, through acquisition 
and sale by one or more wholesalers, manufacturers, or pharmacies, until fi nal 
sale to a pharmacy or other person furnishing, administering, or dispensing 
the dangerous drug”5.
In 2008 China Chinese State Food and Drug Administration (CFDA) made 
serialization mandatory on individual saleable pharmaceutical product units 
for 275 therapeutic classes by December 2011. 6
Brazil in 2009 established rules and provisions for implementation of a nation-
al system of drug product identifi cation and tracking throughout the pharma-
ceutical supply chain, Resolution No. 54, by the Joint Board of the National 
Health Surveillance Agency (ANVISA – Agencia Nacional de Vigilancia San-
itariar)7. 
In France from January, 2011 CIP13 coding legislation defi ned by Agency of 
Sanitary Safety and Health Products (AFSSAPS) requires all prescribed phar-
maceutical products to include a specifi ed data matrix barcode on the outer 
packaging. Manufacturers, distributors, pharmacies and hospitals must trace 
products by electronic receipt notice8.
South Korean Ministry of Health and Welfare notifi cation 2011- 58, amending 
“Controlling and indicating barcodes of pharmaceutical products,” establishes 
new regulations relating to drug traceability. In Turkey in 2012, the Turkish 




6 According to: Pharmaceutical Track-And-Trace Serialization Playbook, 2016 Edition, 
Health Care Packaging, http://www.healthcarepackaging.com/playbooks/pharmaceutical-seri-
alization-playbook (05.2016)
7 According to: Pharmaceutical Serialization Track And Trace (Easy guide to country-wise 
mandates), page 4 https://www.infosys.com/industries/life-sciences/industry-offerings/Docu-
ments/pharmaceutical-serialization-country-wise-mandates.pdf (05.2016)
8 According to: Pharmaceutical Serialization Track And Trace (Easy guide to country-wise 
mandates), page 4 https://www.infosys.com/industries/life-sciences/industry-offerings/Docu-
ments/pharmaceutical-serialization-country-wise-mandates.pdf (05.2016) p.4.
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Pharmaceutical Track and Trace System) to track prescription drug products 
and their shipping cases.
Argentine law requires serializing and tracking using GS1 encoded DataMa-
trix symbols for all unit-level items that are reimbursed. The National Food, 
Drug and Technology Administration (ANMAT), has chosen GS1 Standards 
to identify drugs through the supply chain9. 
In India, serialization begins in 2015. The Indian Directorate General of For-
eign Trade (DGFT) requires GS1-GTIN, serialization and barcodes on tertiary 
(cases), secondary and primary packaging for all pharmaceuticals exported 
from the country10.
In Saudi Arabia, serialization is obligatory after March 23, 2015, and in Jor-
dan after January 1, 2017. In both countries the outer package of prescription 
drug products must contain both a human readable, and a DataMatrix, symbol 
encoded with GS1-GTIN to identify the item, the packaging lot number, expi-
ration date and pack size. 11
3. EU REGULATORY FRAMEWORK
“The high level of human health protection should be ensured in the defi nition 
and implementation of all EU policies and activities”12. In achieving this goal 
producers and distributers should complain to required and expected produc-
tion and distribution standards for different products. 
Falsifi ed medicines are a major threat to public health and safety, since they 
have not been properly evaluated to check their quality, safety and effi cacy - as 
required by strict EU authorization procedures13. It might contain ingredients 
of bad quality or in the wrong dose. As falsifi cations become more sophisti-
9 According to: Pharmaceutical Track-And-Trace Serialization Playbook, 2016 Edition, 
Health Care Packaging, http://www.healthcarepackaging.com/playbooks/pharmaceutical-seri-
alization-playbook (05.2016)
10 According to: Pharmaceutical Track-And-Trace Serialization Playbook, 2016 Edition, 
Health Care Packaging, http://www.healthcarepackaging.com/playbooks/pharmaceutical-seri-
alization-playbook (05.2016)
11 Data according to: Pharmaceutical Track-And-Trace Serialization Playbook, 2016 Edition, 
Health Care Packaging, p.25-26. http://www.healthcarepackaging.com/playbooks/pharmaceu-
tical-serialization-playbook (05.2016)
12 TFEU article 168  https://europadatenbank.iaaeu.de/user/view_legalact.php?id=260 
(05.2016)
13 According to: European Medicine Agency: Falsifi ed medicine, http://www.ema.europa.eu/
ema/index.jsp?curl=pages/special_topics/general/general_content_000186.jsp (05.2016)
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cated, the risk that falsifi ed or counterfeit medicines enter in the EU market 
increases every year. In period 1988-2004 increase in counterfeit seizures was 
1000 %14. Falsifi ed medicines represent a serious threat to global health and 
call for a comprehensive strategy both at European and international level15.
National health measures fall within internal market rules, and medical goods 
and services doesn’t have any special status, and the free movement must be 
guaranteed to the same subject as any other goods or services. 
Most falsifi ed medicine in developed countries is lifestyle expensive products 
hormone, steroids, antihistaminic, corticosteroids, obesity and erectile dys-
function. In developing countries most of falsifi ed medicine is one for life 
threatening diseases oncological, antibiotics, cardiovascular, pain killers.16. 
Fake medicine distribution channels are door to door sale, or legal chain of 
distribution through wholesalers (cca.2%). But the largest channel for fake 
medicine distribution is Internet, over 50%.17
The EU has a strong legal framework for the licensing, manufacturing and 
distribution of medicines. At the end of the distribution chain, only licensed 
pharmacies and approved retailers are allowed to offer medicines for sale, in-
cluding the legitimate sale via the Internet. 
The “Medicrime Convention” is the fi rst international criminal law instrument 
to oblige States Parties to criminalize18 the manufacturing of counterfeit med-
ical products; supplying, offering to supply and traffi cking in counterfeit med-
ical products; the falsifi cation of documents; the unauthorized manufacturing 
or supplying of medicinal products and the placing on the market of medical 
devices which do not comply with conformity requirements.
The Convention provides a framework for national and international co-op-
eration across the different sectors of the public administration, measures for 
coordination at national level, preventive measures for use by public and pri-
14 Atzor Sabine, DG ENTR Study on Distribution Channels: Part I Combating Counterfeit 
Medicines, Stakeholder Meeting 29 November 2006, http://ec.europa.eu/health/fi les/counterf_
par_trade/2006_11_com_pres_counterfeitstrategy_en.pdf (05.2016)
15 WHO estimated that counterfeit and fake medicine are responsible for hundreds thousands 
death in the world Sanofi : The Fight Against Counterfeit Medicines, November, 2015, http://
en.sanofi .com/Images/40228_Presskit_2015-12_Counterfeit_EN_V2.pdf (05.2016) p. 3
16 According to: European Medicine Agency: Falsifi ed medicine, http://www.ema.europa.eu/
ema/index.jsp?curl=pages/special_topics/general/general_content_000186.jsp (05.2016)
17 Sanofi : The Fight Against Counterfeit Medicines, November, 2015, http://en.sanofi .com/
Images/40228_Presskit_2015-12_Counterfeit_EN_V2.pdf (05.2016) p. 5
18 CETS 211 – Counterfeiting of medical products and similar crimes, 28.X.2011:http://www.
coe.int/en/web/conventions/full-list/-/conventions/rms/090000168008482f (05.2016) p.5
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vate sectors and protection of victims and witnesses. Furthermore, it foresees 
the establishment of a monitoring body to oversee the implementation of the 
Convention by the States Parties. 
In July 2011, the EU strengthened the protection of patients and consumers by 
adopting a new Directive on falsifi ed medicines for human use19. The Falsifi ed 
Medicines Directive applies since 2 January 2013. The Directive introduces 
tougher rules to improve the protection of public health with new harmonized, 
pan-European measures to ensure that medicines are safe and that the trade in 
medicines is rigorously controlled. These new measures include20:
• Obligatory safety features on the outer packaging of the medicines, to be 
detailed via a delegated act;
• A common, EU-wide logo to identify legal online pharmacies. This would 
make it easier to distinguish between legal and illegal online pharmacies 
throughout the European Union;
• Tougher rules on the controls and inspections of producers of active phar-
maceutical ingredients; 
• Strengthened record-keeping requirements for wholesale distributors
On 9 February 2016, the European Commission published a delegated reg-
ulation (Commission Delegated Regulation (EU) 2016/161) that introduces 
two safety features to be placed on the packaging of most human medicines: 
a unique identifi er (a 2-dimension barcode) and an anti-tampering device21. 
These safety features will guarantee medicine authenticity for the benefi t 
of patients and businesses, and will strengthen the security of the medicine 
supply chain, from manufacturers to distributors, pharmacies and hospitals. 
Marketing authorization holders must place these on the packaging of most 
prescription medicines and certain non-prescription medicines no later than 9 
February 2019. The annexes of the regulation include the list of medicines sub-
ject to the new requirement22. Regulation (EU) 2016/161 mainly provides for: 
technical characteristics of the unique identifi er (UI), verifi cation of the Safety 
Features, repositories system for the UI, lists of exceptions from bearing/not 
bearing the safety features. European Medical Association (EMA) and the 
19 EU Directive: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:174: 
0074:0087:EN:PDF (05.2016)
20 EU Directive: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= J:L:2011:174:0074: 
0087:EN:PDF (05.2016)
21 Commision Delegated Regulation (EU) 2016/161 of 2 October 2015: http://eur-lex.europa.
eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0161&from=EN (05.2016)
22 According to: European Medicine Agency: Falsifi ed medicine, http://www.ema.europa.eu/
ema/index.jsp?curl=pages/special_topics/general/general_content_000186.jsp (05.2016)
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European Commission have prepared an implementation plan, including regu-
latory requirements and timelines, to guide applicants and marketing authori-
zation holders of centrally authorized medicines in meeting the requirements.
Tamper is packaging that makes tampering apparent to the observer, to some 
degree. Drugs need more care in their packaging than do most other products, 
because any failure in their packaging could result in changes in the drug that 
lead either to a failure to cure to illness to injury or even to death of the pa-
tient. Modern packaging needs to be child resistant and tamper evident. Con-
venience, ease of use, hygiene package integrity and new dispensing methods 
must now also be provided for patient and is part of safety features23.
4. PROCEDURE AND  IT FRAMEWORK
Outer package of each product unit must contain unique identifi er (fi gure 1). 
It consists of24 
• Product code: ISO-compliant (ISO 15459); < 50 characters; globally 
unique; issued by ISO-compliant coding agencies;
• Serial number (max 20 characters; randomized)
• A national reimbursement or identifi cation number (optional)
• Batch number
• Expiry date
Figure 1. structure of product unique identifi er25 
The UI is carried by a 2D barcode (Data Matrix ECC200) printed on the outer 
package of the medicine, minimum printing quality and Human-readable format. 
23 According to: Manoj Shivaji Kumbhar, Naresh Hiraram Choudhary, Deepak Annasaheb 
Dighe, Meera Chandradatt Singh Sinhgad: Tamper Evident Pharmaceutical Packaging – Needs 
and Advances, International Journal of Pharmaceutical Sciences Review and Research, P. 141, 
Available online at www.globalresearchonline.net http://globalresearchonline.net/journalcon-
tents/v13-2/030.pdf  (05.2016)
24 Commision Delegated Regulation (EU) 2016/161 of 2 October 2015: http://eur-lex.europa.
eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0161&from=EN (05.2016)
25 Commision Delegated Regulation (EU) 2016/161 of 2 October 2015: http://eur-lex.europa.
eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0161&from=EN (05.2016)
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The Data Matrix = only 2D barcode allowed for authentication and identifi cation 
of a medicinal product. QR codes are allowed, except for identifi cation and authen-
tication. Multiple UIs are allowed, e.g. in case of multi-language packs intended to 
be marketed in more than one Member State, where each UI contains the specifi c 
national reimbursement/ID number of one of the destination Member States.
Figure 2. Product unique identifi er - 2 D barcode representation on the product 
package26
At product unique identifi er (UI) is printed on the product pack and uploaded in 
a secure repository system, and ATDs are applied on packs as well. When veri-
fying the authenticity of a unique identifi er, manufacturers, wholesalers and per-
sons authorized or entitled to supply medicinal products to the public shall check 
the unique identifi er against the unique identifi ers stored in the repositories sys-
tem (Figure 3. Product verifi cation and decommission). A unique identifi er shall 
be considered authentic when the repositories system contains an active unique 
identifi er with the product code and serial number that are identical to those of 
the unique identifi er being verifi ed. The integrity of the ATD is checked as well. 
Figure 3. Distribution, verifi cation and decommission process27
26 Commision Delegated Regulation (EU) 2016/161 of 2 October 2015: http://eur-lex.europa.
eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0161&from=EN (05.2016)
27 Tosetti Patrizia: Medicines verifi cation in Europe: What to expect in 2019 Stakeholders’ 
workshop 26 February 2016 DG SANTE, http://ec.europa.eu/health/fi les/falsifi ed_medi-
cines/201602_stakeholders_workshop_fi nal.pdf (05.2019)
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To serialization process must be supported by data repository on national 
and EU level. It consists of a central information and data router (‘hub’) and 
national or supranational repositories connected to the hub (Figure 4). The 
main task is to store the information of the product unique identifi er and 
allow the verifi cation/decommissioning of them at any point of the supply 
chain. It is established and managed by stakeholders and supervised by com-
petent authorities. 
Figure 4. Repositories system Architecture28
The repositories system has to ensure: verifi cation of authenticity and decom-
missioning of UI, detection of potential incidents of falsifi cation; interopera-
bility among repositories; commercial, confi dential and personal data protec-
tion; extremely quick response time (300 ms system response time); recording 
of all operations concerning a UI (‘audit trail’) 29.
28 Tosetti Patrizia: Medicines verifi cation in Europe: What to expect in 2019 Stakeholders’ 
workshop 26 February 2016 DG SANTE, http://ec.europa.eu/health/fi les/falsifi ed_medi-
cines/201602_stakeholders_workshop_fi nal.pdf (05.2019)
29 Tosetti Patrizia: Medicines verifi cation in Europe: What to expect in 2019 Stakeholders’ 
workshop 26 February 2016 DG SANTE, http://ec.europa.eu/health/fi les/falsifi ed_medi-
cines/201602_stakeholders_workshop_fi nal.pdf (05.2019)
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CONCLUSION
Information and communication technologies (ITC) have enormous potential 
to improve the quality, safety and effi ciency of healthcare. But in the same 
time as new and innovative space develops a new and innovative way to de-
velop new and innovative way for different illegal activities. ITC solutions 
become not only tool for achieving regulatory requirements, but become key 
technology for interconnecting as well as personals, as companies and coun-
ties and societies. The number, type, and complexity of different medicaments 
which are we using are growing very fast. One of the key issues is to pre-
vent distribution and usage of counterfeits and fake and misbranded products 
threating people’s life and public health. Serialization is in different phases of 
implementation and introduction in number of countries. GS1 Datamatrix30 is 
used in all serialization processes except in China.
To accomplish the successful deployment of a global serialization program, 
fl exibility is the key. The system should not be targeted at a single regulation 
but should be designed to provide building blocks of functionality, which can 
be applied differently to the same products in different regulatory environ-
ments. 
The serialization application process started in pharmaceutical and life sci-
ences with necessity to cope with fake, counterfeit and misbranded products 
and pharmaceutical products specially, threating people’s life and public 
health31. Product counterfeiting is a general problem which importance grows 
in e-commerce environment. Thus serialization in pharmaceutical industries 
is just beginning; it will be base for future development and spreading this 
solution in other industries as well.
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